HHS speaks out on illnesses linked to e-cigarettes

HHS has jumped into the fray over the ongoing investigation into e-cigarettes amid more than 200 lung disease injuries associated with vaping. As of Aug. 27, 215 possible cases of pulmonary illnesses, including one death, have been reported across 25 states. The cause of the illnesses is linked only through the use of e-cigarettes.

The outbreak of lung illnesses has led the CDC to investigate as the number of cases rises. HHS is also getting involved. The issue also highlights how the products have been sold in an unregulated market.

“HHS and the Trump Administration are using every tool we have to get to the bottom of this deeply concerning outbreak of illnesses in Americans who use e-cigarettes,” HHS Secretary Alex Azar said in a statement. “More broadly, we will continue using every regulatory and enforcement power we have to stop the epidemic of youth e-cigarette use. This situation, and the rising tide of youth tobacco use, is a top public health priority for the Trump Administration and every leader at HHS.”

While e-cigarette use is to blame for the illnesses, the cases have not been linked to one specific product or substance. The CDC has sent out a Health Alert Network bulletin to provide information about the issue to clinicians.

As the investigation continues, the CDC has recommended that users of e-cigarettes who are concerned about the illnesses stop using the products, nor buy them off the street or modify the products with other substances.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.